Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, et al. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function Mutations. Cancer Discov. 2017;7(9):973-983.

2016

Welsh KJ, Hermane AT, Zhao Z. Is This Patient Pregnant? Clin Chem. 2016;62(8):1163-4.

Mathieu R, Klatte T, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, et al. Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. BJU Int. 2016;118(2):243-9.

Patri P, Seshan SV, Matignon M, Desvaux D, Lee JR, Lee J, et al. Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy. Kidney Int. 2016;89(2):450-8.

Glass R, Kahn L, Khalid K, Siddiqui MT, Cocker R. Predicting histological subtypes of follicular variant of papillary thyroid carcinoma based on cytomorphology. Can cytomorphology optimize use of molecular testing? J Am Soc Cytopathol. 2016;5(6):345-350.

Choe H, Sboner A, Beltran H, Nanus D, Tagawa ST. PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma. Thromb Res. 2016;140 Suppl 1:S192.

Spina V, Khiabanian H, Messina M, Monti S, Cascione L, Bruscaggin A, et al. The genetics of nodal marginal zone lymphoma. Blood. 2016;128(10):1362-73.

Christensen-Quick A, Lafferty M, Sun L, Marchionni L, DeVico A, Garzino-Demo A. Human Th17 Cells Lack HIV-Inhibitory RNases and Are Highly Permissive to Productive HIV Infection. J Virol. 2016;90(17):7833-47.

Shanmugam V, Geraghty B, DeSimone RA, Hoda RS. Diagnostic value of positive urinary cytology in the detection of recurrent urothelial carcinoma: 10-Year Experience at the Papanicolaou Cytology Laboratory. Diagn Cytopathol. 2016;44(12):975-979.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016;29(4):574-586.